The Centers for Disease Control and Prevention this week alerted health care providers and others to a continued increase in opioid overdose deaths involving fentanyl and its analogs. Among other increases, the number of overdose deaths involving the analog carfentanil, 100 times more potent than fentanyl, nearly doubled in the first half of 2017 in the 10 states reporting preliminary data to CDC, to 815. Health care providers may need to administer multiple doses of naloxone per overdose due to the increased potency of these drugs relative to other opioids, the agency said. “Orally-ingested counterfeit pills laced with fentanyl or fentanyl analogs may require prolonged dosing of naloxone in the [emergency department] hospital setting due to a delayed toxicity that has been reported in some cases,” the advisory notes. CDC recommends that health care providers discuss treatment options with patients who have opioid use disorders and opioid-related overdoses, once stabilized. Post-overdose protocols include prescribing naloxone and connecting patients with case management services or peer navigators to help link them to treatment services, CDC said. In other news, Attorney General Jeff Sessions yesterday announced an initiative to reduce the supply of illicit synthetic opioids, including fentanyl and fentanyl analogs.

Related News Articles

Headline
The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the…
Headline
April 27 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites…
Headline
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the…
Headline
Critical Access Hospitals, certain clinics, and other eligible outpatient facilities that provide primary care or substance use disorder treatment to high-need…
Headline
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels.
Headline
The Agency for Healthcare Research and Quality is accepting comments through April 25 on a draft report on treatment for acute pain.